Rigor Reviewed

Rigor-Reviewed Manuscript

Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer.

Name: Αlpha¹ Rigor Record — Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer.
Item: Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer.
Rating: 59
Author: Αlpha¹

Elez E, Yoshino T, Shen L, Lonardi S, Van Cutsem E, Eng C, Kim TW, Wasan HS, Desai J, Ciardiello F, Yaeger R, Maughan TS, Morris VK, Wu C, Usari T, Laliberte R, Dychter SS, Zhang X, Tabernero J, Kopetz S, BREAKWATER Trial Investigators

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3.25★ (Adequate), 0 critical, 4 high issues for “Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 10, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.25 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ReportingKey resources not met−0.5★
ReportingData & code availability not met−0.5★
ReportingEthical approvals partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.29.0Source: full text

Problems surfaced4 types

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

Reporting gaps3

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data and code not sharedAssessed
Key resources not identifiedAssessed
Ethics/consent reporting incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a methodologically strong phase 3 randomized trial: randomization, blinding of primary endpoints, pre-specified power analysis, detailed methods, and proportional conclusions are all well reported, and the 3 machine-verifiable statistics recomputed consistently. The main weaknesses are reporting gaps rather than scientific flaws: no data availability statement, no manufacturers/sources for investigational products, no statistical software identified, and a vague IRB statement (no named committee/protocol number). Copyedit issues are trivial typographical/punctuation problems.

Both independent reviewers converged on all eight dimension statuses (identical 79/100 scores); the only checklist-level divergences were minor (outlier/missing-data handling in study design; limitations-discussed in reporting transparency), resolved by weighing the cited evidence. The statistics verification covered only 3 tests with a statistic+df or effect+CI; threshold-only p-values and untestable statistics were not verified, so statistics are described only as 'reported tests recomputed consistently', not as fully validated. No retracted or not-found references (22 checked); 1 checked link live; trial registered at ClinicalTrials.gov.

9 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Recomputed 3 tests: 3 consistent, 0 inconsistent; 3 via agent-written checks.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions5 pass · 1 warn · 2 fail

Prior work is cited, including the BEACON trial in previously treated patients and the poor prognosis of BRAF V600E-mutant mCRC. The rationale linking BRAF and EGFR co-targeting to overcome feedback reactivation is logically explained. Limitations of prior work (e.g., chemotherapy alone outcomes) are discussed and addressed by the first-line design.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper clearly establishes the scientific premise by citing prior research (BEACON trial, ANCHOR study) and the rationale for dual BRAF/EGFR inhibition with chemotherapy in the first-line setting.

Evidence

paraphrase[Introduction, paragraph 1-2]

“Based on results from BEACON, encorafenib plus cetuximab, an anti-EGFR monoclonal antibody, was established as standard of care (SOC) for previously treated BRAF V600E-mutant mCRC.”

direct quote[Introduction, paragraph 1]

“In CRC, BRAF inhibition can cause rapid pathway feedback reactivation through epidermal growth factor receptor (EGFR), attenuating its activity.”

View in source

direct quote[Introduction, paragraph 2]

“A first-line activation pathway-targeted treatment that can demonstrate improved efficacy in BRAF V600E-mutant mCRC is needed.”

View in source

PASSReviewer 2· 95% conf

The paper establishes a clear scientific premise, citing prior work (BEACON, ANCHOR) and providing a rationale for combining targeted therapy with chemotherapy in BRAF V600E-mutant mCRC.

Evidence

paraphrase[Introduction, paragraph 3]

“Based on results from BEACON, encorafenib plus cetuximab, an anti-EGFR monoclonal antibody, was established as standard of care (SOC) for previously treated BRAF V600E-mutant mCRC.”

direct quote[Introduction, paragraph 4]

“A first-line activation pathway-targeted treatment that can demonstrate improved efficacy in BRAF V600E-mutant mCRC is needed.”

View in source

direct quote[Introduction, paragraph 3]

“In the first-line setting, chemotherapy with or without a biologic agent (e.g., bevacizumab) was the SOC for BRAF V600E-mutant mCRC and was associated with inferior outcomes versus BRAF wild-type mCRC (median progression-free survival of 5.8 vs. 9.2 months; median overall survival of 11.1 vs. 23.7 months).”

View in source

Randomization was implemented via Interactive Response Technology with stratification by ECOG status and region. The primary endpoint (PFS) was assessed by blinded independent central review. A power analysis with 85% power at a one-sided alpha of 0.023 was pre-specified with a sample size of 235 per arm. Inclusion and exclusion criteria are detailed. The open-label design is stated and the key endpoint is blinded.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Study design is rigorous: randomization is described, power analysis is provided, inclusion/exclusion criteria are clear, and endpoint assessment is blinded. Missing explicit outlier handling for missing data, but ITT analysis is defined.

Evidence

paraphrase[Methods, Trial Design, Patients, and Treatment]

“Patients were randomized 1:1:1 to receive EC... Randomization stratification factors were Eastern Cooperative Oncology Group performance status... and region... Randomization was implemented by Interactive Response Technology.”

paraphrase[Methods, Statistical Analysis]

“The primary analysis of progression-free survival was preplanned to occur after ≥230 events... this number of events was required to have at least 85% power to detect an HR of 0.67 using a one-sided stratified log-rank test at a significance level of 0.023.”

paraphrase[Methods, Statistical Analysis]

“The statistical analysis mentions 'all patients randomized' for efficacy but does not discuss handling of missing data or outliers beyond standard censoring for survival analysis.”

PASSReviewer 2· 95% conf

The study design is rigorous: randomization with stratification, blinded independent central review for primary endpoints, pre-specified power analysis, and inclusion/exclusion criteria are clearly described.

Evidence

paraphrase[Methods, Trial Design]

“Randomization stratification factors were Eastern Cooperative Oncology Group performance status (0 vs. 1) and region (US/Canada vs. Europe vs. Rest of World). Randomization was implemented by Interactive Response Technology.”

paraphrase[Methods, Endpoints]

“The dual primary endpoints are objective response rate (in the first 110 patients randomized in the EC+mFOLFOX6 and SOC arms, respectively [objective response rate subset]) and progression-free survival both by blinded independent central review.”

direct quote[Methods, Statistical Analysis]

“The primary analysis of progression-free survival was preplanned to occur after ≥230 events for the EC+mFOLFOX6 and SOC arms and ≥12 months after the completion of enrollment of the phase 3 portion of the study; this number of events was required to have at least 85% power to detect an HR of 0.67 using a one-sided stratified log-rank test at a significance level of 0.023.”

View in source

Table 1 provides sex, age range, and ECOG performance status for each arm. Weight is not reported. Health status is captured by ECOG. Demographics are extensive, including race, tumor side, stage, primary tumor resection, number of organs involved, liver metastases, and biomarkers. Both sexes are enrolled, so sex justification is not applicable.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthINADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Sex, age, and health status (ECOG) are reported in baseline demographics, but weight is not reported. Demographics including race, tumor side, stage, and biomarker status are comprehensive.

Evidence

paraphrase[Table 1]

“Sex — no. (%) Male: 79 (50.0) [EC], 123 (52.1) [EC+mFOLFOX6], 119 (49.0) [SOC]”

paraphrase[Table 1]

“Age — yr Median: 59.0, 60.0, 62.0; Range: 26.0–84.0, 24.0–81.0, 28.0–84.0”

paraphrase[Table 1]

“Race — no. (%) White: 88 (55.7), 141 (59.7), 144 (59.3); Asian: 64 (40.5), 88 (37.3), 91 (37.4); ...”

PASSReviewer 2· 85% conf

Sex, age, ECOG performance status, and demographics are reported in Table 1, but weight is not reported.

Evidence

paraphrase[Table 1]

“Sex — no. (%) | Male | 79 (50.0) | 123 (52.1) | 119 (49.0) | | Female | 79 (50.0) | 113 (47.9) | 124 (51.0) | | Age — yr | Median | 59.0 | 60.0 | 62.0 | | Range | 26.0–84.0 | 24.0–81.0 | 28.0–84.0”

paraphrase[Table 1]

“Race — no. (%) | White | 88 (55.7) | 141 (59.7) | 144 (59.3) | | Asian | 64 (40.5) | 88 (37.3) | 91 (37.4)”

absence[Table 1]

Weight is not reported.

The paper states that the protocol was approved by 'the relevant ethics committee/institutional review board at each site' but does not name a specific committee or provide a protocol number. Informed consent is described. Regulatory compliance with the Declaration of Helsinki, ICH-GCP, and applicable laws is stated.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementINADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 90% conf

Informed consent and regulatory compliance are adequately reported, but the IRB/ethics committee statement is vague (no named committee or protocol number). This triggers a warning.

Evidence

direct quote[Methods, Trial Oversight]

“The protocol, including amendments, is available at NEJM.org and was approved by the relevant ethics committee/institutional review board at each site.”

View in source

direct quote[Methods, Trial Design, Patients, and Treatment]

“Informed consent was obtained from patients before enrollment.”

View in source

paraphrase[Methods, Trial Oversight]

“BREAKWATER was performed in accordance with consensus ethical principles derived from international guidelines, including the Declaration of Helsinki and CIOMS International Ethical Guidelines, applicable International Conference on Harmonization Good Clinical Practice guidelines...”

WARNReviewer 2· 90% conf

The ethics statement is vague ('approved by the relevant ethics committee/institutional review board at each site') without naming the committee or providing a protocol number, which is inadequate. Informed consent was obtained and regulatory compliance is stated.

Evidence

direct quote[Methods, Trial Oversight]

“The protocol, including amendments, is available at NEJM.org and was approved by the relevant ethics committee/institutional review board at each site.”

View in source

direct quote[Methods, Trial Design, Patients, and Treatment]

“Informed consent was obtained from patients before enrollment.”

View in source

paraphrase[Methods, Trial Oversight]

The drugs (encorafenib, cetuximab, oxaliplatin, leucovorin, 5-FU, bevacizumab) are named with dose and regimen but manufacturer/source is not provided. The statistical analysis software (e.g., SAS, R) is not mentioned. Other resources (antibodies, cell lines, etc.) are not applicable because this is a clinical trial without wet-lab assays.

Sub-criteria

mycoplasma testingN/A

reagents identifiedINADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedNOT REPORTED

Per reviewer (2) — the votes behind the verdict

FAILReviewer 1· 85% conf

Investigational products are identified with dose and regimen but manufacturer/source is not explicitly stated. Statistical software is not identified. Both applicable criteria are not adequate, leading to a fail.

Evidence

paraphrase[Methods, Trial Design, Patients, and Treatment]

“EC (encorafenib 300 mg orally once daily; cetuximab 500 mg/m2 intravenously once every 2 weeks), EC+mFOLFOX6 (encorafenib 300 mg orally once daily; cetuximab 500 mg/m2 intravenously once every 2 weeks; oxaliplatin 85 mg/m2 intravenously, leucovorin 400 mg/m2 intravenously, and 5-FU 400 mg/m2 intravenous bolus, then 5-FU 2400 mg/m2 continuous intravenous infusion over 46–48 hours, all once every 2 weeks [mFOLFOX6; 28-day cycle])”

absence[Methods, Statistical Analysis]

Statistical software is not identified.

FAILReviewer 2· 80% conf

The investigational products (encorafenib, cetuximab, chemotherapy) are named with dosing regimens but manufacturers/sources are not identified. No statistical software is identified.

Evidence

paraphrase[Methods, Trial Design, Patients, and Treatment]

absence[Methods, Trial Design, Patients, and Treatment]

No manufacturer or source is provided for any drug.

absence[Methods, Statistical Analysis]

No statistical software is identified.

Tests named include stratified log-rank test, Cox proportional hazards model, and Kaplan-Meier method. Effect sizes (HR, OR) with 95% CIs are reported. Data presentation includes Kaplan-Meier curves, forest plots, and tables with per-group n. Exact p-values are given as '<0.0001' rather than exact numbers, which is common but imprecise. Statistical software is not mentioned. Assumptions are handled by design (Cox model). Mathematical plausibility is not applicable due to large N and continuous outcomes.

Sub-criteria

tests namedADEQUATE

exact p valuesINADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedNOT REPORTED

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical tests are named, effect sizes with CIs are reported, and data presentation follows clinical trial standards. Exact p-values are reported as thresholds (P<0.0001) rather than exact figures, which is a minor imprecision. Software is not identified, but this does not affect the pass.

Evidence

paraphrase[Methods, Statistical Analysis]

“The primary analysis of progression-free survival was preplanned to occur after ≥230 events... using a one-sided stratified log-rank test at a significance level of 0.023.”

direct quote[Results, Efficacy]

“HR 0.53 (95% CI 0.407, 0.677; two-sided P<0.0001)”

View in source

direct quote[Results, Efficacy]

“two-sided P<0.0001”

View in source

PASSReviewer 2· 90% conf

Statistical tests are named, effect sizes with CIs are reported, data presentation is adequate, and numbers are plausible. However, exact p-values are not reported (only thresholds) and statistical software is not identified.

Evidence

paraphrase[Methods, Statistical Analysis]

“The treatment effect of progression-free survival was evaluated using a Cox proportional hazards model stratified by baseline stratification factors. The HR and its corresponding 95% confidence interval (CI) were reported. The Kaplan–Meier approach was used to estimate median progression-free survival for each arm.”

direct quote[Results, Efficacy]

“HR 0.53 (95% CI 0.407, 0.677; two-sided P<0.0001)”

View in source

absence[Methods, Statistical Analysis]

Statistical software is not identified.

The paper mentions the ClinicalTrials.gov identifier (NCT04607421) and states the protocol is available at NEJM.org, but does not include a statement about where the individual patient data or study datasets can be accessed. No repository deposit or accession numbers are provided. Code sharing is not applicable.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementNOT REPORTED

Per reviewer (2) — the votes behind the verdict

FAILReviewer 1· 95% conf

No data availability statement is provided; the trial registry is listed but does not constitute a data access statement. This is a clear omission for a clinical trial.

Evidence

absence[Entire paper]

Data availability statement is absent.

FAILReviewer 2· 95% conf

No data availability statement is present; no repository deposit, accession numbers, or code sharing are mentioned.

Evidence

absence[Entire manuscript]

No data availability statement is present.

absence[Entire manuscript]

No repository deposit or accession numbers are mentioned.

absence[Entire manuscript]

No code sharing is mentioned.

Methods are detailed with dosing regimens, endpoints, and statistical plans. Trial registration number is provided. All pre-specified primary and secondary endpoints are reported. Limitations (open-label, EC arm closure) are discussed. Conclusions are supported by the data. Funding sources and conflict of interest disclosures are present. No reporting guideline checklist is cited.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Methods are complete, trial is registered, all key outcomes are reported, limitations are discussed, conclusions are proportional, and funding/COI are disclosed. The only missing element is a reference to a reporting guideline (e.g., CONSORT), which is not mentioned.

Evidence

paraphrase[Abstract, Methods, and Funding]

“ClinicalTrials.gov number, NCT04607421”

paraphrase[Discussion]

“EC arm enrollment was closed based on the low likelihood of EC demonstrating superiority versus SOC following the results of the phase 2 ANCHOR study...”

paraphrase[Methods]

“No reference to CONSORT or other reporting checklist is found in the paper.”

PASSReviewer 2· 85% conf

The trial is registered, methods are complete, outcomes are reported, and funding/COI are disclosed. However, no reporting guideline checklist is referenced and limitations are not explicitly discussed.

Evidence

paraphrase[Abstract and Methods]

“ClinicalTrials.gov number, NCT04607421”

absence[Methods]

No reporting guideline checklist is referenced.

absence[Discussion]

No dedicated limitations section is present.

3 copyedit issues flagged: mostly typo, punctuation.

Checked 22 references by DOI: 17 verified — 5 no DOI (shown, not verified).

Reproducibility

1 data/code link checked; 1 live.

Registered (2 IDs: ClinicalTrials.gov). No reporting guideline cited.

Αlpha¹ Rigor Action ItemsFinal pass before journal submission

Post-publication robustness is moderate-to-good: the core design, statistics, and conclusions are sound and the findings are not cast into doubt, but an informed reader should weigh several reporting gaps — the absence of a data-availability statement, unnamed drug manufacturers and statistical software, and the vague IRB statement — which are correctable via an erratum/clarification or trial-record update rather than indicating invalid results. The copyedit issues are trivial and do not affect interpretation.

1.
HIGHdata code
Publish a data availability statement (e.g., via erratum or the article's online note) specifying the mechanism for requesting individual participant data, such as a sponsor-managed data-access committee, YODA, or Vivli.
A published data-driven phase 3 trial with no statement on access to participant-level data is a reproducibility gap that an informed reader will weigh.
2.
HIGHreporting
In the Methods section (Trial Design, Patients, and Treatment), identify the manufacturer/source of encorafenib, cetuximab, and each chemotherapy agent (oxaliplatin, leucovorin, 5-FU).
The key_resources dimension fails because investigational products are named with doses but their sources are not identified, which impairs reproducibility.
3.
HIGHstatistics
State the statistical software and version (e.g., SAS 9.4, R 4.x) used for all analyses in the Statistical Analysis section.
Statistical software is not identified, an omission that limits reproducibility of the analyses.
4.
HIGHethics
In the Trial Oversight section, name the specific ethics committee(s)/IRB(s) that approved the protocol and include the protocol number.
The current IRB statement is too vague to be auditable, which is the basis of the ethical_approvals warn.
5.
MEDIUMstatistics
Report exact p-values (e.g., two-sided P=1.2×10^-6) instead of thresholds like 'P<0.0001' in the Results section.
Threshold-only p-values are a minor imprecision that reduces statistical transparency.
6.
MEDIUMreporting
Reference the CONSORT 2010 statement and indicate that a completed CONSORT checklist and flow diagram are available as supplementary material.
No reporting guideline is referenced, and a CONSORT flow diagram of enrollment/randomization/follow-up is an expected adjunct for a phase 3 trial.
7.
MEDIUMstatistics
Add an explicit statement in the Statistical Analysis section describing how missing data and outliers were handled (e.g., censoring rules, imputation, or confirmation that none was performed).
Missing-data/outlier handling is not explicitly described, which was flagged as a reporting gap in study_design.
8.
MEDIUMcopyedit
Fix the Table 1 C-reactive protein entry for the EC+mFOLFOX6 arm: change '6(25' to '6 (2.5)'.
This is a typographical/formatting error (missing space and percent sign) that could be misread as an impossible value.
9.
LOWcopyedit
Rephrase the Results (Safety) sentence on median duration of treatment to 'In the EC, EC+mFOLFOX6, and SOC arms, the median duration of treatment (range) was 27.0 weeks (2.0–153.6), 49.8 weeks (1.3–161.9), and 25.9 weeks (2.0–150.0), respectively.'
The current sentence is syntactically confusing and warrants a punctuation/clarity fix.
10.
LOWreporting
Include body weight or BMI in the baseline demographics table.
Weight is a standard baseline variable in oncology trials and is currently absent from Table 1.
11.
LOWstatistics
Add a brief note on verification of the proportional-hazards assumption for the Cox model (e.g., inspection of Schoenfeld residuals).
This would strengthen the statistical assumptions_verified reporting for the primary PFS analysis.

Full text (32,559 chars)Analyzed: Aug 10, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside